Kidney transplantation has been studied in 156 papers since 2016: 108 observational studies in people, 3 in animals, 42 reviews; 38 in the past year. Its furthest trials in people are at phase 2. The newest story, Oct 30, 2026: “Incompatible living-donor kidney transplants tied to longer survival”.
Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
45 independent labs in 22 countries
6 findings against
7 trials, none about aging, 1 with no results posted
Funders: National Institute of Diabetes and Digestive and Kidney Diseases and others
Humans107
Animals3
In silico1
What did studies of kidney transplantation find?
45
Studies of kidney transplantation measured 45 outcomes; the most studied are frailty (7 studies), survival (6) and lifespan (3).
Frailty
↓downin humans7−67% patients
7 studies
Kidney transplantation is linked with lower frailty in adults with kidney failure.
Kidney transplantation was not clearly linked with graft survival in humans (kidneys from donors aged 70 or older compared with younger donors) (3-year graft survival 80% vs 88.6% in control group).
Humanskidneys from donors aged 70 or older compared with younger donorskidneys from donors aged 70 years or olderkidneyn = 27
Kidney transplantation was not clearly linked with overall survival in humans (elderly ESRD patients, time-dependent Cox model) (HR = 0.94, p = 0.837).
Kidney transplantation is associated with mortality in humans (Compared with dialysis patients) (SMR 0.39, 95% CI 0.37–0.40; estimated survival advantage 8–11 years).
HumansCompared with dialysis patientsmedian 11.1 years
International journal of surgery (London, England)·
Kidney transplantation is associated with mortality in humans (compared with non-dialysis-dependent CKD patients) (adjusted HR 0.57, 95% CI 0.33-1.01).
Humanscompared with non-dialysis-dependent CKD patientsmedian follow-up period of 88 months
Kidney transplantation is linked with a higher risk of mortality in humans (old-to-old KT recipients vs young recipients) (aHR 2.89, 95% CI 1.14-7.32).
Humansold-to-old KT recipients vs young recipients
Kidney transplantation is linked with a higher risk of mortality in humans (HR 1.15 (95% CI 1.03-1.27)).
HumansKDPI >85% non-preemptive transplant in recipients older than 60 years, first year posttransplant, compared with waitlisthigh KDPI, non-preemptivefirst year posttransplant
Kidney transplantation is linked with a lower risk of mortality in humans (HR 0.61 (95% CI 0.41-0.90)).
HumansKDPI >85% preemptive transplant in recipients older than 60 years, first year posttransplant, compared with waitlisthigh KDPI, preemptivefirst year posttransplant
Transplant international : official journal of the European Society for Organ Transplantation·
Physical frailty
↓downin humans1
1 study
Kidney transplantation is associated with physical frailty in humans (kidney transplant recipients) (8.3% before transplantation to below 2% during follow-up).
Humanskidney transplant recipientsup to 2 yearsn = 230
Kidney transplantation is linked with a higher risk of infection-related hospitalizations in humans (compared with non-dialysis-dependent CKD patients) (HR 3.91, 95% CI 2.66-5.74).
Humanscompared with non-dialysis-dependent CKD patientsmedian follow-up period of 88 months
Kidney transplantation is linked with a higher risk of end-stage renal disease in humans (compared with non-dialysis-dependent CKD patients) (HR 3.51, 95% CI 1.07-11.5).
Humanscompared with non-dialysis-dependent CKD patientsmedian follow-up period of 88 months
Kidney transplantation is associated with cardiovascular events in humans (compared with non-dialysis-dependent CKD patients) (HR 1.31, 95% CI 0.42-4.05).
Humanscompared with non-dialysis-dependent CKD patientsmedian follow-up period of 88 months
Ten-year survival was 86.3% after incompatible living-donor transplants versus 56.8% with standard waitlist care in matched patients aged 60 or older.Ten-year survival was 86.3% after incompatible living-donor transplants versus 56.8% with standard waitlist care in matched patients aged 60 or older.
Who was studied1,819 patients aged ≥60 years, 10-year, against the CWS group
What changedTen-year patient survival was higher after desensitized living-donor kidney transplantation than standard waitlist care: 86.3% versus 56.8%
The catchPropensity score matching cannot eliminate all differences between the treatment and waitlist groups
Among 34,758 adults, 29.9% received bone density testing within a year of transplantation, compared with 63.8% over a median 8.4-year follow-up.Among 34,758 adults, 29.9% received bone density testing within a year of transplantation, compared with 63.8% over a median 8.4-year follow-up.
Kidneys 100-fold larger than those previously rewarmed with this method recovered function after up to one year at minus 150 degrees Celsius.Kidneys 100-fold larger than those previously rewarmed with this method recovered function after up to one year at minus 150 degrees Celsius.
Physical frailty fell from 8.3% to below 2%, and mild cognitive impairment dropped from 42.6% to 31.3% over two years in 230 kidney transplant recipients.Physical frailty fell from 8.3% to below 2%, and mild cognitive impairment dropped from 42.6% to 31.3% over two years in 230 kidney transplant recipients.
Among 75-year-olds, estimated five-year survival was 59% after expanded-criteria donor transplants following circulatory death versus 55% with continued dialysis, without…Among 75-year-olds, estimated five-year survival was 59% after expanded-criteria donor transplants following circulatory death versus 55% with continued dialysis, without a statistically clear difference.
Who was studied64,036 dialysis patients waitlisted for first deceased-donor kidney transplants
What changedAt age 75 years, five year survival with expanded-criteria circulatory-death donor kidneys did not differ clearly from dialysis: 59% versus 55%
The catchUnrecorded changes in frailty and cardiovascular risk could inflate the estimated transplant survival benefit